28 completed, 8 terminated, 4 recruiting, 3 withdrawn. 46 Phase 1, 15 Phase 2.
Follow entinostat: new trials by email Literature Review of entinostat trials Research Report on entinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities Entinostat, VAC/VTC chemotherapy - Soft Tissue Sarcoma | Phase 1 | Recruiting | Beijing Tongren Hospital | 16 | 2025-03-15 | 2026-10-22 |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-02 | 2024-08-05 | |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Brachyury-TRICOM, Entinostat, M7824 - Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2021-05-04 | 2022-01-11 |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Atezolizumab, Carboplatin, Entinostat - Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 3 | 2021-04-27 | 2025-10-03 |
| A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma Entinostat, FOLFOX regimen - Pancreas Cancer | Phase 1 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2021-01-01 | 2021-01-15 | |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer Entinostat, Enzalutamide - Prostate Adenocarcinoma | Phase 1 | Terminated | George Washington University | 6 | 2019-05-01 | 2021-08-02 |
| A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy Entinostat, Capecitabine - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Completed | University of Virginia | 13 | 2019-01-29 | 2022-11-01 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 144 | 2017-12-22 | 2025-11-10 |
| To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer hydroxychloroquine, entinostat, regorafenib - Colorectal Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 20 | 2017-10-02 | 2023-11-09 |
| A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function Entinostat - Renal Impairment, Healthy Volunteer | Phase 1 | Completed | Syndax Pharmaceuticals | 40 | 2017-07-27 | 2018-04-13 |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Atezolizumab, Bevacizumab, Entinostat - Metastatic Cancer, Renal Cancer | Phase 1 / Phase 2 | Terminated | Roberto Pili | 31 | 2017-06-29 | 2025-03-20 |
| Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Entinostat, Pembrolizumab - Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2017-06-23 | 2025-03-25 |
| A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects Entinostat, Midazolam - Drug Interaction, Healthy Volunteer | Phase 1 | Completed | Syndax Pharmaceuticals | 26 | 2017-05-23 | 2018-08-16 |
Showing 20 of 46. Sign in to see all of them.
Breast Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (8) · Neoplasms (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Breast Diseases (4) · Lung Neoplasms (4) · Pancreatic Neoplasms (4) · Bronchial Neoplasms (3) · Fallopian Tube Neoplasms (3) · Kidney Neoplasms (3) · Leukemia, Myeloid, Acute (3) · Lung Diseases (3) · Myelodysplastic Syndromes (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3)
National Cancer Institute (NCI) (18) · Syndax Pharmaceuticals (13) · Abramson Cancer Center at Penn Medicine (2) · Beijing Tongren Hospital (1) · George Washington University (1) · Hoffmann-La Roche (1) · Kyowa Kirin Co., Ltd. (1) · National Institutes of Health Clinical Center (CC) (1) · Roberto Pili (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Taizhou EOC Pharma Co., Ltd. (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Hospital Heidelberg (1) · University of Virginia (1)
United States (38) · China (4) · Australia (1) · Austria (1) · France (1) · Georgia (1) · Germany (1) · Israel (1) · Japan (1) · Netherlands (1) · South Korea (1) · Sweden (1) · Switzerland (1)
Michael Meyers, MD, PhD (4) · Laura Sterling, MD (2) · Patricia M LoRusso (2) · Alex Adjei (1) · Amer M Zeidan (1) · Andrew Baildam, MD (1) · Andrew Bukowinski (1) · David S Schrump, M.D. (1) · Dennis Slamon, MD (1) · Fatima H Karzai, M.D. (1) · Hongqian Guo, PhD (1) · Howard A Burris, M.D. (1) · Hoyoung M Maeng, M.D. (1) · Ivana Gojo (1)
PMID 39863139, PMID 19546476, PMID 19652201, PMID 22586682, PMID 26577691, PMID 32503469, PMID 33203644, PMID 34196874, PMID 34563945, PMID 34819039, PMID 35552447, PMID 37555284, PMID 38036712, PMID 38356965
U01CA070095 (6), P30CA006973 (4), UM1CA186689 (4), UM1CA186691 (3), UM1CA186717 (2), 2017 (1), 2018 (1), P30CA016056 (1), P30CA016672 (1), P30CA118100 (1), R21CA137649 (1), R21CA161561 (1), U01CA062461 (1), U01CA062505 (1), U01CA069854 (1)